Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GERN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGERNGeron$1.58+1.0%$1.31$1.04▼$2.01$1.02B0.615.79 million shs4.68 million shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGERNGeron+4.70%+22.83%+38.05%-11.36%+12.23%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGERNGeron$1.58+1.0%$1.31$1.04▼$2.01$1.02B0.615.79 million shs4.68 million shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGERNGeron+4.70%+22.83%+38.05%-11.36%+12.23%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGERNGeron 2.00Hold$2.5058.73% UpsideCurrent Analyst Ratings BreakdownLatest GERN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/23/2026GERNGeron Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/26/2026GERNGeron Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/27/2026GERNGeron Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 7/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGERNGeron$183.88M5.49N/AN/A$0.35 per share4.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGERNGeron-$83.50M-$0.11N/A15.75N/A-35.48%-23.31%-10.08%8/5/2026 (Estimated)Latest GERN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2026Q2 2026GERNGeron-$0.01N/AN/AN/A$55.21 millionN/A5/6/2026Q1 2026GERNGeron-$0.03-$0.01+$0.02-$0.01$50.59 million$51.84 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGERNGeronN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGERNGeron0.526.784.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGERNGeron73.71%Insider OwnershipCompanyInsider OwnershipGERNGeron1.71%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGERNGeron70641.52 million630.55 millionOptionableGERN HeadlinesRecent News About These CompaniesGeron (NASDAQ:GERN) Stock Crosses Above Two Hundred Day Moving Average - Here's What HappenedJuly 8 at 3:41 AM | americanbankingnews.comGeron Corporation: Commercial Performance Could Dovetail With IMpactMF Run-UpJuly 1, 2026 | seekingalpha.comGeron Corporation (NASDAQ:GERN) Given Average Recommendation of "Hold" by AnalystsJune 30, 2026 | americanbankingnews.comGeron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 18, 2026 | globenewswire.comGeron Corporation (GERN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 8, 2026 | seekingalpha.comAfter Plunging 26.6% in 4 Weeks, Here's Why the Trend Might Reverse for Geron (GERN)June 4, 2026 | zacks.comGeron to Participate in the Goldman Sachs 47th Annual Global Healthcare ConferenceJune 1, 2026 | globenewswire.comGeron: Time To Reconsider This Oversold BiotechJune 1, 2026 | seekingalpha.comGeron Shareholders Expand Equity Plan and Elect DirectorsMay 27, 2026 | tipranks.comGeron Earnings Call Highlights Growth, Pricing PressuresMay 21, 2026 | theglobeandmail.comGeron (GERN) Loses 21.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerMay 19, 2026 | zacks.comGeron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 18, 2026 | globenewswire.comGeron Corporation (GERN) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 12, 2026 | seekingalpha.comGeron Corporation Announces Positive Real-World Evidence Study of RYTELO® in Lower-Risk Myelodysplastic Syndromes Ahead of EHA 2026 PresentationsMay 12, 2026 | quiverquant.comQFirst Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026May 12, 2026 | globenewswire.comIs Geron (GERN) One of the Best US Stocks Under $5 to Buy?May 11, 2026 | insidermonkey.comGeron Corporation (NASDAQ:GERN) Just Reported And Analysts Have Been Lifting Their Price TargetsMay 10, 2026 | finance.yahoo.comA Look At Geron (GERN) Valuation After Q1 Results And Reaffirmed 2026 GuidanceMay 10, 2026 | finance.yahoo.comGeron Earnings Call Highlights RYTELO-Driven MomentumMay 7, 2026 | tipranks.comGeron (GERN) Q1 2026 Earnings Call TranscriptMay 7, 2026 | fool.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGERN Company DescriptionsGeron NASDAQ:GERN$1.58 +0.02 (+0.96%) As of 11:52 AM Eastern This is a fair market value price provided by Massive. Learn more.Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Rivian’s 75 Million-Share Offering Turns the R2 Growth Story Into a Dilution Test Sony Is Going All-Digital—But Investors Should Watch This Instead Scotiabank Sees a New Growth Story for Cloudflare Why Exxon Could Be the Market's Next Big Comeback Stock Why Penguin Solutions May Be the Smartest AI Infrastructure Stock The Market Just Got Shaken—These 3 ETFs May Come Out Stronger Meta Platforms’ Cloud Push: Growth Opportunity Versus AI Concerns A Market Panic Just Discounted the AI Highway's Tollbooth Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
